Answers are grounded in this paper and cite their sources.
Review explores the development of RSV live-attenuated vaccines to prevent disease in RSV-seronegative infants and children, highlighting advances and future directions.
Human respiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract illness (LRTI) in infants, young children, and the elderly. Although long-acting monoclonal antibodies and subunit and messenger ribonucleic acid (mRNA) vaccines can protect infants (6 months and older) via passive and active immunization, respectively, a critical protection gap remains for RSV-seronegative infants and young children (6 months and younger). For this RSV-seronegative population, intranasal live-attenuated vaccines (LAVs) have emerged as promising formulations owing to the key advantage of lacking vaccine-associated enhanced respiratory disease (VAERD) following natural RSV infection in vaccine recipients, as supported by numerous clinical trials conducted in this vulnerable population. Furthermore, intranasal RSV LAVs can induce the full spectrum of protective immune responses against RSV, including systemic and local immunity, neutralizing antibodies, secretory IgA (SIgA), and tissue-resident memory CD8 + T (T RM ) cells. Although Sanofi’s recently developed RSVt (RSV/ΔNS2/Δ1313/I1314L) failed to achieve the expected efficacy in a phase 3 clinical trial, there are other types of RSV LAV candidates constructed via the deletion of the M2-2 gene showing improved efficacy during the clinical studies, and other potential strategies available to boost the immunogenicity of RSV LAVs. Due to the sustained efforts over the past 58 years, many significant advances have been made not only in technology to generate RSV LAVs, such as reverse genetics, but also in the insights on many issues, including attenuation design, evaluation criteria for attenuation and immune efficacy, the stepwise strategy for clinical research in RSV-seronegative children, as well as the importance of ensuring global vaccine accessibility. In this review, we explore past and current efforts to develop safe and effective RSV LAVs and outline future directions to prevent RSV disease in RSV-seronegative populations through their use of RSV LAVs.
No takes yet. Share an insight, caveat, or question.
虞结梅 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: